7 completed, 2 terminated. 5 Phase 2, 3 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 4 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Urate Oxidase: new trials by email Literature Review of Urate Oxidase trials Research Report on Urate Oxidase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome Pegloticase, Rasburicase - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 4 | Completed | M.D. Anderson Cancer Center | 10 | 2022-04-05 | 2026-05-06 |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies rasburicase, allopurinol - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Terminated | Roswell Park Cancer Institute | 24 | 2011-09-29 | 2018-01-09 |
| Rasburicase for Hyperuricemia rasburicase (SR29142) - Nutritional and Metabolic Diseases | Phase 2 | Completed | Sanofi | 30 | 2005-06-01 | 2009-03-30 |
| Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma doxorubicin hydrochloride, cyclophosphamide, methotrexate - Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma | Phase 2 | Completed | Children's Oncology Group | 97 | 2004-06-01 | 2014-09-19 |
| Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Rasburicase (SR29142), Allopurinol - Tumor Lysis Syndrome, Cancer | Phase 3 | Completed | Sanofi | 280 | 2004-04-01 | 2010-01-12 |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Rasburicase (SR29142) - Tumors, Hyperuricemia | Phase 4 | Completed | Sanofi | 94 | 2004-03-01 | 2009-03-30 |
| Fasturtec TLS Treatment / Prophylysis urate oxidase - Tumor Lysis Syndrome | Phase 4 | Completed | Sanofi | 45 | 2003-07-01 | 2008-04-03 |
| Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma Rasburicase (SR29142) - Hyperuricemia, Leukemia | Phase 2 | Completed | Sanofi | 50 | 2003-04-01 | 2009-10-02 |
| Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma Rasburicase (SR29142) - Hyperuricemia | Phase 2 | Terminated | Sanofi | 33 | 2002-07-01 | 2012-03-07 |
Hyperuricemia (5) · Leukemia (4) · Lymphoma (4) · Tumor Lysis Syndrome (4) · Burkitt Lymphoma (2) · Neoplasms (2) · Blast Crisis (1) · Congenital Abnormalities (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myelodysplastic Syndromes (1) · Nutritional and Metabolic Diseases (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Sanofi (6) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (6) · Japan (2) · Belgium (1) · France (1) · Germany (1) · Italy (1)
Eunice Wang, MD (1) · Mitchell Cairo, MD CCRP (1) · Sharon Chang (1) · Sreedhar Mandayam, MD (1)
P30CA016056 (1), U10CA098543 (1)